Compare SPRY & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRY | PLSE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.4M | 3.6B |
| IPO Year | 2020 | 2015 |
| Metric | SPRY | PLSE |
|---|---|---|
| Price | $4.14 | $53.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $22.00 |
| AVG Volume (30 Days) | ★ 1.4M | 578.9K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $87.40 | $840.00 |
| Revenue Next Year | $81.64 | $287.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.12 | $12.56 |
| 52 Week High | $13.15 | $58.90 |
| Indicator | SPRY | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 25.28 | 59.44 |
| Support Level | N/A | $15.64 |
| Resistance Level | $8.61 | $58.90 |
| Average True Range (ATR) | 0.27 | 4.57 |
| MACD | -0.12 | -0.62 |
| Stochastic Oscillator | 2.76 | 52.82 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.